BR112018069941A2 - derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf - Google Patents

derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf

Info

Publication number
BR112018069941A2
BR112018069941A2 BR112018069941A BR112018069941A BR112018069941A2 BR 112018069941 A2 BR112018069941 A2 BR 112018069941A2 BR 112018069941 A BR112018069941 A BR 112018069941A BR 112018069941 A BR112018069941 A BR 112018069941A BR 112018069941 A2 BR112018069941 A2 BR 112018069941A2
Authority
BR
Brazil
Prior art keywords
disorders
modulators
imidazole derivatives
fused pentacyclic
tnf activity
Prior art date
Application number
BR112018069941A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul Heer Jag
Keyaerts Jean
Elsa Lépissier Luce
Alexander Lowe Martin
Louis Robert Deligny Michaël
Original Assignee
Sanofi Sa
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Ucb Biopharma Sprl filed Critical Sanofi Sa
Publication of BR112018069941A2 publication Critical patent/BR112018069941A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112018069941A 2016-04-01 2017-03-31 derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf BR112018069941A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16163579 2016-04-01
PCT/EP2017/057767 WO2017167994A1 (en) 2016-04-01 2017-03-31 Fused pentacyclic imidazole derivatives as modulators of tnf activity

Publications (1)

Publication Number Publication Date
BR112018069941A2 true BR112018069941A2 (pt) 2019-02-05

Family

ID=55650327

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018069941A BR112018069941A2 (pt) 2016-04-01 2017-03-31 derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf

Country Status (8)

Country Link
US (1) US10654861B2 (cg-RX-API-DMAC7.html)
EP (1) EP3436460B1 (cg-RX-API-DMAC7.html)
JP (1) JP6968090B2 (cg-RX-API-DMAC7.html)
CN (1) CN109195968B (cg-RX-API-DMAC7.html)
BR (1) BR112018069941A2 (cg-RX-API-DMAC7.html)
CA (1) CA3019245A1 (cg-RX-API-DMAC7.html)
EA (1) EA201892142A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017167994A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CA3117344A1 (en) * 2018-10-24 2020-04-30 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of tnf activity
JP2025540024A (ja) 2022-11-23 2025-12-11 フォワード セラピューティクス, インコーポレイテッド TNF-α活性の調節因子
TW202513567A (zh) * 2023-06-09 2025-04-01 大陸商上海翰森生物醫藥科技有限公司 五環類衍生物抑制劑、其製備方法與應用
WO2025038927A1 (en) 2023-08-16 2025-02-20 Raythera, Inc. Modulators of tnf alpha activity and uses thereof
WO2025212627A1 (en) 2024-04-03 2025-10-09 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2026055519A1 (en) 2024-09-06 2026-03-12 Rapt Therapeutics, Inc. Fused ring imidazole compounds
WO2026112363A1 (en) 2024-11-21 2026-05-28 Rapt Therapeutics, Inc. Fused heterocyclic aromatic compounds and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087720A1 (en) 2003-03-10 2004-10-14 Pfizer Inc. Phosphate/sulfate ester compounds and pharmaceutical compositions for inhibiting protein interacting nima (pin1)
TW200615273A (en) * 2004-11-10 2006-05-16 Nicholas Piramal India Ltd Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha
DE102008030206A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
TW201242953A (en) 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
ES2576298T3 (es) 2011-06-20 2016-07-06 Vertex Pharmaceuticals Incorporated Ésteres de fosfato de inhibidores de girasa y topoisomerasa
CA2874303C (en) * 2012-06-11 2020-10-13 Ucb Biopharma Sprl Tnf -alpha modulating benz imidazoles
ES2689429T3 (es) * 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321729D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321730D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
ES2885432T3 (es) 2014-10-03 2021-12-13 Ucb Biopharma Sprl Derivados de imidazol pentacíclicos condensados

Also Published As

Publication number Publication date
EA201892142A1 (ru) 2019-04-30
EP3436460A1 (en) 2019-02-06
JP6968090B2 (ja) 2021-11-17
CN109195968A (zh) 2019-01-11
CN109195968B (zh) 2022-02-11
JP2019512533A (ja) 2019-05-16
EP3436460B1 (en) 2021-08-18
US20190100525A1 (en) 2019-04-04
US10654861B2 (en) 2020-05-19
WO2017167994A1 (en) 2017-10-05
CA3019245A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
BR112018069937A2 (pt) derivados de imidazol hexacíclicos fundidos como moduladores de atividade do tnf
BR112018069936A2 (pt) derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf
BR112017006669A2 (pt) derivados de imidazol pentacíclico fundido
BR112016012990A2 (pt) Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf
BR112016012997A2 (pt) Derivados de benzimidazóis tricíclicos fundidos como moduladores de atividade de tnf
CO2019012856A2 (es) Derivados de imidazol pentacíclico fusionado como moduladores de la actividad de tnf
BR112014030940A2 (pt) benzimidazóis que modulam tnf-alfa
BR112016012242A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf
BR112016012261A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf
BR112016011794A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112016013012A2 (pt) Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf
BR112016012243A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112016011484A2 (pt) Derivados de imidazopirimidina como moduladores de atividade de tnf
BR112016012253A2 (pt) Compostos derivados de imidazol e pirazol, composição farmacêutica e uso dos compostos
BR112016013018A2 (pt) Derivados heteroaromáticos bicíclicos fundidos como moduladores de atividade de tnf
BR112016011483A2 (pt) Derivados de imidazotriazina como moduladores de atividade de tnf
MX386752B (es) Agonistas del receptor farnesoide x y usos de los mismos.
MX381313B (es) Derivados de benzimidazol como moduladores de ror-gamma
BR112016011485A2 (pt) Derivados de imidazopiridazina como moduladores de atividade de tnf
EA201500130A1 (ru) Производные имидазопиридина в качестве модуляторов активности tnf
BR112016011789A2 (pt) Derivados de purina, composição farmacêutica compreendendo os mesmos e uso dos mesmos
BR112016011527A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112016012254A2 (pt) Derivados de triazolpiridazina como moduladores de atividade de tnf
BR112017025601A2 (pt) imidazopirazinas tricíclicas fundidas como moduladoras da atividade de tnf
BR112018069931A2 (pt) derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]